Piper Thomas, Thevis Mario
Center for Preventive Doping Research - Institute of Biochemistry, German Sport University Cologne, Köln, Germany.
European Monitoring Center for Emerging Doping Agents (EuMoCEDA), Cologne/Bonn, Germany.
Drug Test Anal. 2022 Nov;14(11-12):1891-1903. doi: 10.1002/dta.3361. Epub 2022 Aug 31.
In 2020, the confirmation of the non-endogenous origin of several pseudo-endogenous steroids by means of isotope ratio mass spectrometry (IRMS) was recommended by the World Anti-Doping Agency (WADA), in addition to previously established target analytes for IRMS in sports drug testing. To date, however, IRMS-based methods validated in accordance with current WADA regulations have not been available. Therefore, the aim of this research project was the development and validation of a method to determine the carbon isotope ratios (CIR) of all newly considered pseudo-endogenous steroids, encompassing the anabolic androgenic steroids comprising a 1-ene-core structure (5α-androst-1-ene-3β,17β-diol, 5α-androst-1-ene-3,17-dione [1AD], 17β-hydroxy-5α-androst-1-en-3-one, 3α-hydroxy-5α-androst-1-ene-17-one [1AND], and 3β-hydroxy-5α-androst-1-ene-17-one [1EpiAND]), as well as steroids referred to as hormone and metabolic modulators (androsta-1,4,6-triene-3,17-dione [TRD] and its main metabolite 17β-hydroxy-androsta-1,4,6-triene-3-one) and 6α- and 6β-hydroxy-androst-4-ene-3,17-dione. With peak purity of target analytes being critical for IRMS analyses, a twofold high-performance liquid chromatography (HPLC)-based sample purification was employed, with all analytes being acetylated between the first and second HPLC fractionation. Using established gas chromatography/combustion/IRMS instrumentation, limits of quantification were estimated at 10 ng/ml for a 20 ml urine aliquot for all analytes, except for 1AND (20 ng/ml), and combined measurement uncertainties were estimated between 0.4‰ and 0.9‰. For proof-of-concept, samples collected after the single oral administration of a nutritional supplement containing 1AD and 1EpiAND were analyzed as well as existing excretion study urine samples obtained after the administration of 4-androstenedione and TRD. Based on the obtained results, the developed method was considered to be fit-for-purpose.
2020年,世界反兴奋剂机构(WADA)建议通过同位素比率质谱法(IRMS)确认几种假内源性类固醇的非内源性来源,这是对体育药物检测中IRMS先前已确定的目标分析物的补充。然而,迄今为止,尚未有符合WADA现行规定的基于IRMS的方法。因此,本研究项目的目的是开发并验证一种方法,用于测定所有新纳入的假内源性类固醇的碳同位素比率(CIR),这些类固醇包括具有1-烯核心结构的合成代谢雄激素类固醇(5α-雄甾-1-烯-3β,17β-二醇、5α-雄甾-1-烯-3,17-二酮[1AD]、17β-羟基-5α-雄甾-1-烯-3-酮、3α-羟基-5α-雄甾-1-烯-17-酮[1AND]和3β-羟基-5α-雄甾-1-烯-17-酮[1EpiAND]),以及被称为激素和代谢调节剂的类固醇(雄甾-1,4,6-三烯-3,17-二酮[TRD]及其主要代谢物17β-羟基-雄甾-1,4,6-三烯-3-酮)和6α-及6β-羟基-雄甾-4-烯-3,17-二酮。由于目标分析物的峰纯度对IRMS分析至关重要,因此采用了基于高效液相色谱(HPLC)的双重样品净化方法,所有分析物在第一次和第二次HPLC分级分离之间进行乙酰化处理。使用已建立的气相色谱/燃烧/IRMS仪器,除1AND(20 ng/ml)外,所有分析物20 ml尿液等分试样的定量限估计为10 ng/ml,联合测量不确定度估计在0.4‰至0.9‰之间。为了进行概念验证,对单次口服含有1AD和1EpiAND的营养补充剂后收集的样品以及服用4-雄烯二酮和TRD后获得的现有排泄研究尿液样品进行了分析。基于获得的结果,所开发的方法被认为是适用的。